1. Introduction {#s0005}
===============

One of the significant challenges in radiation therapy of brain cancers is its negative impact on normal brain functions, which often limits the level of radiation that can be safely administered. Radiation therapy to the central nervous system (CNS) results in neurocognitive defects commonly recognized as the late effects of radiation therapy [@bib1], [@bib2]. In experimental animals, cranial irradiation causes persistent oxidative stress and neuroinflammation [@bib3], [@bib4], [@bib5] and a subsequent reduction in hippocampal neurogenesis and attrition of dendritic structures [@bib6], [@bib7], [@bib8], [@bib9]. Antioxidant enzymes, including the extracellular superoxide dismutase (EC-SOD) and the mitochondrially targeted catalase, used within the context of transgenic animals have shown promising radiation protection of normal cognitive functions via preservation of hippocampal neurogenesis and dendritic structures [@bib8], [@bib10]. The data suggested that antioxidant supplements may be beneficial for normal tissue protection against radiation damage in the CNS.

To translate the basic research findings into clinical practice, the genetic approach needs to be replaced with pharmacological agents for ease of administration. The Mn porphyrin (MnP)-based redox active drugs are developed based on structure-activity relationship for their actions as SOD mimics [@bib11]. The biologically compatible reduction potential of MnPs allows them to oxidize and reduce superoxide equally well, thus functioning as both anti- and pro-oxidants. A large body of studies over the years suggests that MnPs can also undergo diverse interactions with other reactive species, such as reducing peroxynitrite, oxidizing ascorbate, and oxidizing simple and protein thiols [@bib12]. The thermodynamic and kinetic factors that control SOD-like activity of the Mn porphyrin center also control other redox reactions such as ONOO-- reduction, H~2~O~2~ dismutation and reduction, and ·NO oxidation [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19].

The radioprotective effects of MnPs have been demonstrated in several cellular and animal models, and most recently in normal brains, salivary glands, and mouth mucosa [@bib20], [@bib21]. Moreover, *in vitro* and *in vivo* studies showed differential effects of MnPs on cancer and normal tissues that implied radio- and chemosensitization of cancer tissues and protection of normal tissues [@bib11], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24]. In this study we first examined three MnPs to identify the best drug to be tested for radioprotection of hippocampal neurogenesis. Based on the biodistribution data in the brain and the lack of overt toxicity, MnBuOE was chosen for follow-up studies.

2. Materials and methods {#s0010}
========================

2.1. Animal studies {#s0015}
-------------------

Male and female C57BL/6J mice (Jackson Laboratory) were used for various studies starting at 2 months of age. Mice were housed in a pathogen-free facility under standard housing conditions. All animal protocols were reviewed and approved by the IACUC committee at the VA Palo Alto Health Care System and were consistent with the Public Health Service Policy on Humane Care and Use of Laboratory Animals.

2.2. MnP administration {#s0020}
-----------------------

Three MnPs were tested in this study: MnE (Mn(III) *meso*-tetrakis(*N*-ethylpyridinium-2-yl)porphyrin, MnTE-2-PyP^5+^, BMX-010), MnHex (Mn(III) *meso*-tetrakis(*N*-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP^5+^), and MnBuOE (Mn(III) *meso*-tetrakis(*N*-n-butoxyethylpyridinium-2-yl)porphyrin, MnTnBuOE-2-PyP^5+^, BMX-001). Based on previous pharmacokinetics, toxicology, and efficacy studies [@bib11], [@bib13], [@bib20], [@bib21], [@bib24], [@bib25], a daily dose of 3 mg/kg of each MnP was used. Mice received either two daily subcutaneous (sc) injections (2×1.5 mg/kg) for 7--14 days, or continuous infusion for 2--6 weeks using a model 1004 Alzet® osmotic pump loaded with 28.4 mg/ml MnP. The concentration was calculated to maintain a total daily dose of 3 mg/kg in a 25 g mouse, which was the average weight of male C57BL/6J mice at 2 months of age. All MnP solutions were diluted in PBS and sterilized with 0.22 µm filters before use.

2.3. Tissue preparation and LC-MS/MS analyses of MnPs {#s0025}
-----------------------------------------------------

Samples were prepared and analyzed as described [@bib25] with modifications to accommodate small tissue sizes and enhance detection sensitivity. Detailed procedures are described in [Supplementary Data](#s0080){ref-type="sec"}.

2.4. Hippocampal neurogenesis studies {#s0030}
-------------------------------------

Only male mice and MnBuOE were used for neurogenesis studies. The dosing schedules are as depicted in experimental timelines in [Figs. 2](#f0010){ref-type="fig"} and [S3](#s0080){ref-type="sec"}. Irradiated mice received a single dose of 5 Gy cranial irradiation using a Mark I gamma irradiator as described [@bib8], [@bib26], [@bib27], [@bib28]. Immunohistochemical staining and quantification of neuronal populations in the hippocampal dentate gyrus were performed as described [@bib8], [@bib26], [@bib27], [@bib28].

2.5. Western blot analyses of protein *S*-glutathionylation {#s0035}
-----------------------------------------------------------

To know if administration of MnBuOE and irradiation led to higher levels of protein *S*-glutathionylation, we treated a separate set of mice with MnBuOE for 7 days followed by a single dose of cranial irradiation. Tissue processing, western blotting, and image analyses were performed as described [@bib8], [@bib28], [@bib29]. The primary antibodies were anti-glutathione (GSH) (ViroGen, clone D8, 1:2,500) and GAPDH (Sigma, clone GAPDH-71.1, 1:2,500), and a goat anti-mouse IgG tagged with IRDye® 800CW (Li-Cor, 1:10,000) was used as the secondary antibody.

2.6. Statistical analyses {#s0040}
-------------------------

GraphPad Prism 7 was used for statistical analyses. Student\'s *t*-test was used for simple pair-wise comparisons; one- or two-way analysis of variance (ANOVA) followed by Holm-Sidak\'s multiple comparisons test was used for comparisons across multiple cohorts. All data are reported as mean±SEM. Sample sizes are specified in the figure legends.

3. Results {#s0045}
==========

3.1. Tissue levels of Mn porphyrins {#s0050}
-----------------------------------

We tested three different MnPs -- MnE, MnHex, and MnBuOE ([Fig. 1](#f0005){ref-type="fig"}A and B) -- for their tissue distributions in a 10-day injection study. Acute toxicities from MnHex were observed in 2 mice after 6 days of administration; all other mice appeared to be healthy and their body weights were maintained at a steady level ([Fig. S1A](#s0080){ref-type="sec"}). LC-MS/MS analyses showed micromolar concentration of MnPs in the liver, with MnHex showing the highest level, followed by MnBuOE and MnE ([Fig. 1](#f0005){ref-type="fig"}C). Consistent with the chemical structure (i.e. increased lipophilicity) that allows MnBuOE and MnHex to cross the blood brain barrier, nanomolar concentrations of MnBuOE and MnHex were detected in various brain regions while only trace amounts of MnE were detected ([Figs. 1](#f0005){ref-type="fig"}C and [S1B--D](#s0080){ref-type="sec"}). Both MnBuOE and MnHex accumulated at significantly higher levels in the hippocampus than in the cortex ([Fig. 1](#f0005){ref-type="fig"}C), with MnBuOE showing a 6-fold difference between the two regions. Because of the observed MnHex acute toxicity, and the potential for long-term toxicity, MnBuOE was chosen for the efficacy studies of radiation protection of hippocampal neurogenesis.Fig. 1**Structures and tissue levels of Mn porphyrins (MnPs). A,** chemical structures of the three MnPs used in this study. **B,** the redox properties of Mn porphyrins expressed in terms of metal-centered reduction potential of Mn^III^P/Mn^II^P redox couple, E~1/2~, (in mV vs NHE) (left panel), the rate constant for the catalysis of O~2~^.−^ dismutation expressed in log units (middle panel), and the lipophilicity, which controls bioavailability, expressed in terms of the Mn porphyrin distribution between n-octanol and water (right panel). Data are taken from [@bib18]. **C,** MnP levels in the liver, hippocampus, and cortex following a 10-day sc administration of 1.5 mg/kg×2 per day. Liver values were measured from individual mice; hippocampal values were measured from samples pooled from 2 to 3 mice each; cortical values for MnBuOE and MnE were measured from individual mice; cortical values for MnHex were measured from samples pooled from 2 mice each. Sample sizes are indicated on the bar graph. **D,** cumulative plasma MnBuOE levels from a 6-week administration (3 mg/kg/day via pump with a loading dose of 1.5 mg/kg×2 via sc injection on day 1). Submandibular bleeding was used for weekly blood collection. Plasma samples collected from individual mice were analyzed. Second order polynomial line fit: X=51.01+24.81\*X+(−0.42)\*X^2^. Samples sizes from week 1 to week 6 are: 12, 12, 9, 9, 6, and 6. **E,** MnBuOE levels in various brain regions after 2, 4, or 6 weeks of continuous administration by osmotic pumps. Plasma levels from these three time points were plotted for side-by-side comparisons. Tissues from individual mice were analyzed. Sample sizes for each brain region were 3, 3 and 6 for the 2-, 4- and 6-week measurements, respectively. OB, olfactory bulb; BS, brainstem; CB, cerebellum; TH, thalamus; HP, hippocampus; Ctx, cortex; P, plasma.Fig. 1

The biodistribution of MnBuOE and MnHex was further tested in a 6-week continuous infusion study. Whereas the plasma showed a steady increase of both MnPs during the 6-week period ([Figs. 1](#f0005){ref-type="fig"}D and [S2A](#s0080){ref-type="sec"}), brain levels plateaued and did not show significant changes over 6 weeks of infusion ([Figs. 1](#f0005){ref-type="fig"}E and [S2B](#s0080){ref-type="sec"}). The average hippocampal MnBuOE levels were about 50% of that detected in the 10-day injection study and were 2.4-fold higher than the cortical levels. In contrast, the hippocampal MnHex levels were comparable to that of the 10-day sc injection study. Consistent with the higher toxicity noted above, two out of 9 mice treated with MnHex died around 4 weeks of MnHex administration.

3.2. Hippocampal neurogenesis {#s0055}
-----------------------------

The first study was conducted with mice receiving sc injections of MnBuOE one day prior to or one day after irradiation for a total of 7 days ([Fig. 2](#f0010){ref-type="fig"}A). No radiation protection was observed with either dosing schedule, and the number of immature neurons (neurons stained positive for the doublecortin (Dcx) protein) was significantly reduced in all irradiated cohorts ([Fig. 2](#f0010){ref-type="fig"}C, left panel). The data, combined with known pharmacokinetics of MnBuOE, suggested that longer duration of administration to reach a higher MnBuOE tissue level before irradiation may be necessary to provide effective radiation protection.Fig. 2**Efficacy of MnBuOE in radiation protection of hippocampal neurogenesis.** Stereological cell counting was used for determining total number of Dcx positive (Dcx+) neurons, BrdU positive (BrdU+) cells, and the production of newborn neurons (BrdU+/NeuN+) and newborn astroglia (BrdU+/GFAP+) in the hippocampal dentate gyrus. **A** and **B,** experimental timelines for the 7-day and 2-week MnBuOE administration, respectively. The day of cranial irradiation was designated as Day 0, and the time points for tissue collections for downstream analyses were indicated. **C,** total number of Dcx+ neurons in the hippocampal dentate gyrus. The intervals between irradiation and tissue collection were indicated in the x-axes. In the 7-day administration study, tissues were collected 6 or 8 days after irradiation from mice that started MnBuOE administration one day before or one day after cranial irradiation, respectively. All the other three cohorts (vehicle/0 Gy, vehicle/5 Gy, and MnBuOE/0 Gy) were sacrificed for tissue collection on day 7. **D,** total number of immature (left panel) and mature (right panel) Dcx+ neurons in the cohorts from the 2-week MnBuOE administration study. **E,** total number of BrdU positive cells in the subgranular zone of hippocampal dentate gyrus at 4 or 8 weeks after cranial irradiation. **F,** lineage analysis of BrdU positive cells in the 8-week cohorts for the production of newborn neurons (BrdU+/NeuN+) and astroglia (BrdU+/GFAP+). One-way ANOVA (C and D) and two-way ANOVA (E and F) followed by Holm-Sidak\'s multiple comparisons test. Adjusted p values are reported. Sample size: n=4 each in the 7-day injection study; n=5 each in the 2-week injection study.Fig. 2

Accordingly, one week treatment with MnBuOE before irradiation ([Fig. 2](#f0010){ref-type="fig"}B) showed a positive effect in radiation protection of hippocampal neurogenesis ([Fig. 2](#f0010){ref-type="fig"}C--F). Consistent with previous study results from EC-SOD transgenic mice [@bib8], higher tissue levels of MnBuOE did not protect Dcx+ neurons from the acute effects of radiation damage when Dcx+ neurons were examined at 48 h after irradiation.

However, at 4 weeks after irradiation, MnBuOE-treated mice produced 31.4% more Dcx+ neurons than the vehicle-treated controls ([Fig. 2](#f0010){ref-type="fig"}C, right panel). Detailed analyses revealed that the higher number of Dcx+ neurons seen in the MnBuOE-treated mice was due to the presence of 51.7% more categories E&F Dcx+ neurons, which were neurons with more extensive dendritic arbors [@bib30] ([Fig. 2](#f0010){ref-type="fig"}D, right panel). Despite the significant increase in Dcx+ neurons, the extent of progenitor cell proliferation was not improved, and the number of BrdU+ cells in the subgranular zone of hippocampal dentate gyrus was similar between the vehicle- and MnBuOE-treated mice at this time point ([Fig. 2](#f0010){ref-type="fig"}E).

At 8 weeks after cranial irradiation, the number of Dcx+ neurons in the hippocampal dentate gyrus were comparable between the vehicle- and MnBuOE-treated cohorts ([Fig. 2](#f0010){ref-type="fig"}C and D). However, a modest but significant increase in BrdU+ cells was observed ([Fig. 2](#f0010){ref-type="fig"}E), suggesting an enhanced long-term survival of newborn cells from MnBuOE administration. Cell lineage analysis of BrdU+ cells showed a significantly higher number of newborn neurons (BrdU+/NeuN+ cells) in MnBuOE-treated mice, whereas the number of newborn astroglia (BrdU+/GFAP+ cells) were comparable between the two cohorts ([Fig. 2](#f0010){ref-type="fig"}F). The data suggested that MnBuOE treatment starting one week prior to and continued for another week after cranial irradiation supported long-term survival of newborn neurons.

Interestingly, prolonged administration of MnBuOE for 6 weeks did not gain additional improvement in hippocampal neurogenesis after cranial irradiation ([Fig. S3](#s0080){ref-type="sec"}), and the number of Dcx+ and BrdU+ cells were similar between vehicle- and MnBuOE-treated cohorts ([Figs. S3B-C](#s0080){ref-type="sec"}). However, within the Dcx+ population, there was a 23% reduction in the categories A-D and a 57% increase in categories E&F Dcx+ neurons ([Fig. S3B](#s0080){ref-type="sec"}).

3.3. Protein *S*-glutathionylation {#s0060}
----------------------------------

In the cortex, MnBuOE and irradiation both contributed significantly to increases in protein *S*-glutathionylation ([Fig. 3](#f0015){ref-type="fig"}A), and the level in irradiated/MnBuOE-treated mice showed a significant increase from that of the irradiated/vehicle-treated controls. In contrast, hippocampus from the same experimental animals showed similar levels of protein *S*-glutathionylation across the various treatment groups ([Fig. 3](#f0015){ref-type="fig"}B). The hippocampal response (or the lack thereof) was similar to that observed in the liver ([Fig. 3](#f0015){ref-type="fig"}C) which was protected from the radiation source during the irradiation procedure.Fig. 3**Protein*****S*****-glutathionylation.** The level of protein *S*-glutathionylation was determined following 7 days of MnBuOE administration (1.5 mg/kg×2 per day, sc) and/or a single dose of 5 Gy cranial irradiation. Cranial irradiation was performed 4--5 h after the final MnBuOE injection, and tissues collected 3 days later. **A,** cortex; **B,** hippocampus; and **C,** liver. Representative images are shown in the upper panels and quantification of total protein *S*-glutathionylation from western blot images are shown in the lower panels. Signal intensities were normalized to that of GAPDH within each sample. Two-way ANOVA followed by Holm-Sidak\'s multiple comparisons test. In the cortex, MnBuOE and irradiation both contributed significantly to the differences in the level of protein *S*-glutathionylation (two-way ANOVA; MnBuOE, *F*~(1,12)~=11.62, p=0.0052; irradiation, *F*~(1,12)~=9.564, p=0.0093). Sample size, n=4 each.Fig. 3

4. Discussion {#s0065}
=============

In this study we showed that lipophilicity of MnPs dictated their brain distribution, and that MnP levels in the brain did not change during 6 weeks of continuous administration even though the plasma level gradually increased over the same treatment period. We also showed the efficacy of MnBuOE in radiation protection of normal hippocampal neurogenesis when the experimental animals received daily MnBuOE administration for one week prior to and one week after irradiation. Interestingly, extending administration of MnBuOE to 6 weeks did not improve post-radiation hippocampal neurogenesis beyond what was achievable from the two-week administration. Given that MnBuOE is now in clinical trial as a radioprotector of normal brain tissues in glioma patients (trial [NCT02655601](ctgov:NCT02655601){#ir0005}), this study result has particular clinical relevance.

The SOD-like activities of MnE, MnHex and MnBuOE were determined with cytochrome *c* assay, which was previously shown to give rise to identical data as pulse radiolysis study [@bib31], and were calculated to be 17-, 33- and 15- fold lower, respectively than that of SOD enzymes [@bib18]. However, differences in lipophilicity and structural characteristics dictated their bioavailability in different tissues [@bib13], [@bib25], [@bib32], [@bib33], [@bib34]. Except for the octyl analog, MnHex bioavailability is the highest among the MnPs examined to date [@bib16], [@bib25], [@bib35], [@bib36]. Consistent with those findings, MnHex levels were higher than MnBuOE in most brain regions examined ([Figs. 1](#f0005){ref-type="fig"}, [S1 and S2](#s0075){ref-type="fn"}). The higher bioavailability of MnHex likely contributes to its higher toxicity in experimental animals seen in this and previous studies [@bib18], [@bib37]. On the other hand, the high bioavailability also makes the efficacious doses of MnHex as low as 0.05 mg/kg (see below).

Extensive toxicity studies were done on all three compounds [@bib11], [@bib18], [@bib25], [@bib38], [@bib39], and data from more recent studies suggested that none were toxic at the efficacious dose [@bib25], [@bib40], [@bib41], [@bib42]. While efficacious at the very low dose of 0.05 mg/kg, MnHex had the median toxic dose (TD~50~) measured at 12.5±2.8 mg/kg by subcutaneous administration [@bib38]. At such high concentrations, mice develop severe shivers and hypotonia, in part due to a drop in blood pressure, within several seconds of administration [@bib38]. Histopathology performed at the end of a long-term study (0.5−2.5 mg/kg×2 per day×4 weeks) showed acute degeneration of hippocampal neurons, mild subcutaneous inflammation, degeneration and regeneration of subcutaneous muscles, and pigment accumulation in Kupffer cells ([@bib18] and Batinic-Haberle et al., unpublished data). However, all mice recovered and showed no overt pathological changes after a 4-week washout period ([@bib18] and Batinic-Haberle et al., unpublished data). The amount of MnHex used in this study was 4 folds below the TD~50~, but within the range that caused histopathological changes during long-term administration. Consistent with the histopathology findings, we observed gross tissue deformation in the small number of mice that died mid-way through the administration period. A recent study showed the radioprotective effects of MnBuOE on salivary glands and mouth mucosa at a maintenance dose as low as 0.1 mg/kg [@bib43] and suggested that MnHex might have been radioprotective of hippocampal neurogenesis at much lower doses than the one we used in this study.

The MnP measurements showed sample-to-sample variations in some brain regions; some differences were also found in MnP concentrations across brain compartments in two separate studies. The variabilities observed may be ascribed to (a) the heterogeneity of MnP in the tissue, (b) small tissue sample size, such as the hippocampi that weighed 10--15 mg each, (c) the low nanomolar range of MnP concentration which was close to the lower limit of quantification of the LC-MS/MS assay, and (d) the different dynamics of MnP distribution/elimination governed by the different administration methods (daily sc injection vs. continuous pump infusion).

The post-radiation neurogenesis pattern in MnBuOE-treated mice was similar to that observed in EC-SOD transgenic mice with increased number of categories E&F Dcx+ neurons at 4 weeks after irradiation and enhanced long-term survival of newborn neurons ([Fig. 2](#f0010){ref-type="fig"}), although the efficacy was modest compared to that from EC-SOD transgenes [@bib8]. Categories E&F Dcx+ neurons have more extensive dendritic outgrowth and branching and are thought to be further along in the maturation process [@bib30]. These more matured Dcx+ neurons should have the advantage of developing into fully functional granule cells, and they likely contributed to the higher number of BrdU+/NeuN+ cells in MnBuOE-treated mice.

Given that the 2-week MnBuOE treatment was efficacious in preserving hippocampal neurogenesis following cranial irradiation, it was somewhat surprising that the 6-week treatment failed to perform better ([Fig. S3](#s0080){ref-type="sec"}). We switched to osmotic pump infusion for the 6-week study to reduce stress associated with daily injections. The different administration methods may have contributed to different pharmacokinetics in the tissues such that the hippocampal MnBuOE levels delivered by osmotic pump were roughly half of that delivered by daily injections even though the total daily doses remained the same. Given the different levels of biodistribution and treatment durations, it was difficult for a direct comparison of results from these two studies. Nevertheless, the consistent improvement of hippocampal neurogenesis following cranial irradiation in the MnBuOE-treated cohorts in two separate studies lends strong support to using MnBuOE as the mitigating agent for radiation-associated late effects in the CNS.

Recent data strongly suggest that the major *in vivo* action of MnPs may be the pro-oxidative action at the level of protein thiols, rather than direct scavenging of small reactive species (e.g. O~2~^-^) [@bib23], [@bib29], [@bib44], [@bib45]. Such action depends on the presence of H~2~O~2~ and GSH, and its magnitude is directly proportional to the levels of H~2~O~2~, redox-active drugs, and exogenous H~2~O~2~ generators in the target tissues. Due to its high abundance in tissues and cells, GSH levels in general were not known to be a limiting factor of MnP-mediated protein *S*-glutathionylation unless the production of GSH is specifically blocked [@bib29], [@bib46]. Recent proteomic studies suggested NF-κB to be a major target, and Keap1 to a lesser degree, of MnP-driven catalysis of *S*-glutathionylation [@bib45]. We therefore attempted to see the impact of radiation and MnBuOE on protein *S*-glutathionylation. The lack of increase in total protein *S*-glutathionylation in the hippocampus from treatments with MnBuOE and irradiation was unexpected given the increases seen in the cortex ([Fig. 3](#f0015){ref-type="fig"}). Differences between the hippocampus and cortex may have contributed to this outcome, and they include the tissue levels of MnBuOE, capacities for H~2~O~2~ metabolism, their anatomical locations, and the level of reactive species generated by ionizing radiation as it traverses through the tissues. Consequently, it is difficult to interpret the *S*-glutathionylation results without additional studies into the potential changes in the NF-κB and Keap1/Nrf2 signaling pathways and the magnitude of oxidative stress incurred in each brain region.

5. Conclusion {#s0070}
=============

Our previous studies showed MnBuOE to be efficacious in reducing normal tissue injuries and enhancing sensitivity of cancers to radiation and chemotherapies [@bib13], [@bib20], [@bib21], [@bib23], [@bib47], [@bib48]. This study expands the normal tissue benefits of MnBuOE to post-irradiation hippocampal neurogenesis, and provides a strong translational support for the current clinical trial of using MnBuOE as a radioprotector. Whether the enhanced hippocampal neurogenesis parallels preserved cognitive functions after cranial irradiation will need to be examined in future studies. The different *S*-glutathionylation outcomes between cortex and hippocampus following MnBuOE treatment and irradiation likely signal differential responses to the treatments. The causes and consequences of such differential response will need to be investigated further in order to optimize treatment conditions to provide a balanced overall benefit to the CNS in patients undergoing cranial radiation therapy. Finally, ionizing radiation leads to multifaceted changes in the CNS. In addition to persistent redox imbalance and inflammation, neurotrophic factor productions are also altered [@bib8], [@bib49], [@bib50]. Consequently, multidisciplinary treatment including redox active drugs and trophic factors administered, as demonstrated recently [@bib28], at different stages of radiation therapy will likely result in the most favorable outcome in reducing normal tissue damage and increasing functional recovery of the CNS.

Appendix A. Supplementary material {#s0080}
==================================

Figure S1Supplementary material

We thank Xinli Guo for the excellent animal care; Vivian Liao, Melody Khosravi, and David Marash-Whitman for assistance in tissue processing, and Dr. Margaret Tome (University of Arizona) for the consultation in protein *S*-glutathionylation analysis. This work was supported by funding from the VA Merit review BX-0024-71 (TTH), seed grant from Palo Alto Veterans Institute for Research (TTH), NIH/NCI Duke Comprehensive Cancer Center Core Grant (5-P30-CA14236-29) (IS), NC Biotechnology Center BIG Award (\#2016-BIG-6518) (IBH, IS and AT), BioMimetix JVLLC (IBH, IS, TW and AT) (186103), Department of Radiation Oncology (IBH), and Brazilian CNPq (402976/2012-6, 485443/2012-0, 552500/2011-9, and 307348/2013-0) and CAPES (24001015030P-4) grants (RSS). We also acknowledge supports from the VA Palo Alto Health Care System for the use of resources and facilities.

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.redox.2017.04.027](http://doi:10.1016/j.redox.2017.04.027){#ir0010}.
